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Abstract: 
A recent outbreak of Zika virus in Brazil has led to a simultaneous increase in reports of 
neonatal microcephaly. Zika targets cerebral neural precursors, a cell population essential for 
cortical development, but the cause of this neurotropism remains obscure. Here we report 
that the neural RNA-binding protein Musashi-1 (MSI1) interacts with the Zika genome and 
enables viral replication. Zika infection disrupts the binding of MSI1 to its endogenous targets, 
thereby deregulating expression of factors implicated in neural stem cell function. We further 

show that MSI1 is highly expressed in neural progenitors of the human embryonic brain, and 
is mutated in individuals with autosomal recessive primary microcephaly. Selective MSI1 
expression in neural precursors could therefore explain the exceptional vulnerability of these 
cells to Zika infection.  


Main text: 
Zika virus (ZIKV) recently emerged as a major public health risk because of its 
devastating effect on fetal neurodevelopment (1-3). ZIKV was first isolated in Uganda in 1947, 
and the virus subsequently spread through Asia, and from there to the Americas (4). A 
causal link between ZIKV infection and congenital brain malformations became apparent in 
2016 following an outbreak in Brazil (1). Brazilian ZIKV is closely related to the Asian-lineage 

strain, which affected New Caledonia and French Polynesia, where cases of microcephaly 
were reported retrospectively (5).  
Intrauterine infections can impair neurodevelopment (6), but ZIKV is highly 
neurotropic and interferes specifically with fetal brain development causing microcephaly, 
cortical malformations and intracranial calcifications (7-10). We hypothesized that the single-
stranded RNA flavivirus ZIKV may hijack RNA-binding factors present in the developing 
central nervous system (11). Host RNA-binding proteins are known to interact with 
untranslated regions (UTRs) to regulate replication, translation and stabilization of viral 
genomes (11). In silico analysis of the genomic RNA of the Brazilian ZIKV strain, PE243, 
revealed three consensus binding sites in the 3’UTR for the highly conserved Musashi family 

of RNA binding proteins, Musashi-1 (MSI1) and Musashi-2 (MSI2), both important 
translational regulators in stem cells (12-15). Two sites were conserved between PE243 and 
the Ugandan MR766 strains (Sites 1, 2), whereas the third (Site 3) was found only in the 
Asian-lineage strains including PE243 (Fig. 1A; Fig. S1A, B). By mapping these sites onto a 
predicted secondary structure of ZIKV 3’UTR, we found all the three to be present on stem-
loop structures, which are considered optimal for MSI binding (16, 17). Moreover, a recent 
study revealed nucleotide substitutions proximal to Sites 1 and 2 in the Asian-lineage strains, 
which could indicate positive selection for MSI1 binding during ZIKV evolution (18). 
To address if the Musashi proteins interacted with ZIKV, we first tested their binding 
to ZIKV 3’UTR. RNA pull-downs identified binding of MSI1, but not MSI2, to the 3’UTR of 

PE243 (Fig. 1B) (15). Mutating the three consensus MSI1 sites in the 3’UTR of PE243 
significantly weakened this interaction (Fig. 1C, D; Fig. S1C). We also confirmed binding 
between MSI1 and the 3’UTR of MR766 (Fig. 1C). To investigate whether MSI1 also binds 
ZIKV 3’UTR in vivo, ultraviolet (UV) crosslinking and RNA immunoprecipitation (CLIP) was 
performed from PE243-infected U-251 glioblastoma cells, revealing a robust direct 
interaction between MSI1 and PE243 ZIKV RNA (Fig. 1E). Consistently, in ZIKV-infected 
cells, MSI1 co-localised with double-stranded RNA, a viral replication intermediate, as 
visualised by confocal and STED super-resolution microscopy (Fig. 1F, G). These data 
confirm an interaction between MSI1 and ZIKV RNA, which is at least in part mediated by the 
3’UTR of the virus.  



To investigate whether MSI1 had an impact on the life cycle of ZIKV, we used RNA 
interference to deplete the protein in U-251 glioblastoma, SK-N-BE2c neuroblastoma and H9 
derived neural stem cells (NSC) and performed PE243 viral infections. In all three cell types 
MSI1 depletion led to a marked reduction in viral RNA levels (Fig. 2A, B).  We then 
generated MSI1 knockouts (KO) in U-251 cells by CRISPR/Cas9-mediated targeting of 
exons 8 or 6 of MSI1 (KO1 and KO2, respectively; Fig. 2C; Fig. S2). Control cells were 
obtained through clonal expansion of cells transfected with Cas9 alone. By measuring viral 
RNA at different times following PE243 infection, a marked reduction of viral load was seen 
in KO1 and KO2 cells at 24 and 48 hours (Fig. 2D). Whereas extensive cell death precluded 
RNA analysis in the controls at 72 hours, viral RNA was comparable between the 48- and 

72-hour timepoints in the KO cells. Consistently, levels of the viral dsRNA and flavivirus E 
protein as well as the infectious titre were reduced in the KOs (Fig. 2E; Fig S3). Because 
MSI2 levels were similar between control and KO cells (Fig. 2C), MSI1 and MSI2 are unlikely 
to have complete functional redundancy in ZIKV replication. Replication of the MR766 strain 
was also impaired in the KO cells (Fig. 2F). In summary, we identify MSI1 as an important 
factor for ZIKV replication, both in primary and transformed neural cell lines.  
Since there was no discernible difference between ZIKV binding and entry into control 
and KO cells (Fig. 2G, H), we asked if MSI1 could regulate translation through ZIKV UTRs. 
To this end, luciferase RNA flanked by the 5’ and 3’UTRs of PE243, was transfected with 
increasing amounts of MSI1 into HEK293T cells, which do not normally express MSI1 (Fig. 

S4). We observed a modest MSI1-driven increase in luciferase expression. The ability of 
MSI1 to promote ZIKV UTR-driven translation in vitro raises the possibility that it performs a 	
similar function in vivo. Alternatively, MSI1 might stabilise the viral RNA genome and/or 
regulate its cyclization or synthesis. In addition, given the pleiotropic roles of MSI1 in cellular 	
pathways, it is plausible that MSI1-dependent regulation of gene expression contributes to 
the ZIKV life cycle (19). However, MSI1 is unlikely to act through general pro- or anti-viral 	
pathways as infection with H1N1 influenza virus was unaffected by MSI1 expression levels 
(Fig. S5). In line with published work, we also find that MSI1 KO cells exhibited defective 	
migration, increased doubling time and cell cycle delay (Fig. S6) (17, 20, 21). Because ZIKV 
replication requires cyclin-dependent kinase activity, such pro-proliferative effects exerted by 	

MSI1 might contribute to virus production (22). Nevertheless, the direct interaction between 
MSI1 and the ZIKV genome is consistent with the hypothesis that the protein promotes some 

aspect of the viral life cycle. 
ZIKV predominantly infects neural progenitors in human fetal brain. We find MSI1 to 

be highly enriched in neural precursors of the ventricular and subventricular zones of the 
human embryonic brain, but absent from mature neurons (Fig. 3A; Fig. S7). Owing to its high 



levels in neural progenitors, and its ability to stimulate ZIKV replication, MSI1 could be 
instrumental to ZIKV-induced cytopathicity in the fetal brain. In addition, MSI1 is required for 

neurodevelopment in both invertebrates and vertebrates, with MSI1-depleted zebrafish 
displaying microcephaly, and mutant mice exhibiting a thin cerebral cortex and reduced 


number of mature neural cell types among other morphological brain abnormalities (14, 19, 
23-25). We have identified a consanguineous Turkish family in which two siblings displayed 
clinical features suggestive of autosomal primary microcephaly (MCPH), a condition 
associated with a significant reduction in cerebral cortex size, but a structurally normal brain 
(Fig. S8A, B) (26, 27). Exome sequencing uncovered potentially deleterious homozygous 
mutations in MSI1, ACACB, DKK4 and DTX3L (Fig. S8C-F, Tables S1 and S2). Of these 
only MSI1 is known to have neural functions, but because mutations were present in four 
genes, the p. Ala184Val point mutation in MSI1 may not be the sole cause of MCPH in these 
individuals (referred to as MSI1A184V). Nevertheless, we have three lines of evidence showing 
that A184V mutant MSI1 is functionally impaired. First, MSI1A184V patient cells exhibit 

premature chromosome condensation (PCC), the same phenotype as MSI1-deficient 
glioblastoma cells. Second, we show that the A184V mutation impedes RNA binding of MSI1, 
leading to deregulated expression of its endogenous targets. Third, we find that the A184V 
mutant MSI1 is unable to support ZIKV replication.  
The PCC phenotype seen in MSI1A184V patient cells has been previously described in 
cells deficient of the MCPH-associated protein, Microcephalin (MCPH1) (Fig. S8G) (28, 29). 
Since the MCPH1 locus is unaffected in MSI1A184V patients, we speculated that MSI1 could 
control chromosome condensation by regulating MCPH1 expression. To determine if MCPH1 
was a MSI1 target, we performed RNA immunoprecipitation under native conditions. In 
addition to its known targets NUMB, p21WAF and the MCPH-associated gene, 

CDK6/MCPH12, MSI1 co-precipitated with two isoforms of MCPH1 (MCPH1_S and 
MCPH_L) despite their divergent 3’ UTRs, but did not interact with other MCPH genes tested 
(Fig. S9A, B) (12, 30, 31). CLIP and RNA mobility shift assays suggest a direct interaction 
between MSI1 and MCPH1_L (Fig. 3B, C). MSI1 can act as a translational suppressor (i.e. 
for NUMB and p21WAF1) or activator (i.e. for CDK6) (12, 21, 30). Consistent with a role for 
MSI1 in translational activation of MCPH1, we observed low MCPH1 protein levels in 
MSI1A184V patient and MSI1-deficient U-251 cells and a reduction in polysome-associated 
MCPH1 transcripts in KO cells (Fig. 3D, E; Figs. S9C, S10). Given that MSI1 interacts with 
ZIKV RNA, and viral RNA is abundant in the infected cell, it could compete with endogenous 
targets for binding MSI1. Indeed, upon ZIKV infection of U-251 cells, we observed a marked 

reduction in the interaction between MSI1 and its target RNAs including MCPH1 and NUMB, 


accompanied by changes in their protein levels that mirrored those of MSI1 KO cells (Fig. 
3F,G).  
 MSI1 interacts with target transcripts via its two RNA recognition motifs (RRM) (19, 
30, 32).  NMR studies show that the conserved Ala184 within the RRM2 is an RNA-binding 
residue (33). Modeling based on the crystal structure of the RNA-binding protein HRP1 with 
RNA, indicates that the A184V mutation impairs the MSI1-RNA interaction (Fig. 4A). To 
evaluate the effect of A184V on MSI1 function in cells, transgenes encoding wild-type and 
A184V MSI1 (MsiWT and MsiAV, respectively) were randomly integrated into KO1 or KO2 U-
251 cells and single clones were isolated (KO1/2-MsiWT or KO1/2-MsiAV). MSI1 protein 

expression in these clones was quantified with respect to endogenous protein levels in 
parental cells (Fig. 4B). When compared to KO2-MsiWT cells, MSI1 RIP recovered 2-4 fold 
fewer target transcripts from KO2-MsiAV, indicative of reduced RNA binding by the A184V 
mutant (Fig. 4C). NUMB and MCPH1 protein levels changed accordingly (Fig. 4B). These 
results were recapitulated in HEK293T cells expressing Msi1WT or Msi1AV (Fig. S11). 
MSI1A184V, MSI1 KO, KO1/2-MsiAV and MSI1-depleted cells all exhibited suboptimal MCPH1 
protein levels and PCC, prompting us to investigate if a functional link existed between these 
phenotypes (Fig. S9C-F). MCPH1 overexpression reduced PCC frequency in MSI1-depleted 
cells, thereby confirming a role for MSI1 in chromosome condensation via translational 
control of MCPH1 (Fig. S8G, H). Therefore, the A184V mutation impairs binding of MSI1 to 

RNA, which leads to reduced MCPH1 expression and a concomitant increase in PCC 
frequency. Remarkably, defective chromosome condensation has been recently found to 
cause MCPH (34).  
Given that the A184V mutation impedes binding of MSI1 to RNA, we next probed the 
effect of A184V mutant MSI1 on ZIKV replication. To this end, viral RNA levels and cell 
viability were assayed in KO1/2, KO1/2-MsiWT and KO1/2-MsiAV U-251 cells infected with 
PE243. Complementation of KO1/2 cells with MsiWT increased both ZIKV RNA levels and 
cell death (Fig. 4D, E). By contrast, MsiAV was unable to support ZIKV replication, and 
showed minimal impact on cell viability. Additionally, in HEK293T cells, expression of MsiWT, 
but not MsiAV, increased viral RNA and cell death upon infection (Fig. 4F, G; Fig. S12). 

These findings also imply that MSI1 expression increases susceptibility of HEK293T cells to 
ZIKV infection (35). Furthermore, we noted an apparent dose-dependent effect of MSI1 on 
viral replication; those U-251 and HEK293T clones that express higher levels of MSI1 
displayed greater viral RNA levels and increased cell death (Fig. 4B, D-G; Figs. S11 and 
S12).  
Our study raises the question whether MSI1 could have functions in other flaviviruses. 
We have surveyed putative MSI1 binding sites in a number of flaviviruses by mapping the 

	
consensus (A/GU(1-3)AG) onto predicted secondary structures of flaviviridae 3’UTRs obtained 
from a recent publication (Table S3) (16). Although several flaviviruses harbour consensus 
MSI1 sites within appropriate structural landscapes, whether MSI1 is relevant to the biology 

of these viruses remains to be established. Furthermore, while our data are consistent with a 
role for MSI1 in ZKV neurotropism and pathology, multiple factors must collude in ZIKV 
infection of the fetal brain, not least viral entry receptors that allow the virus to cross the 
placental barrier (36). Viruses such as human cytomegalovirus and Rubella can also access 
the developing fetal brain, but whether MSI1 contributes to their replication or pathogenesis 
is unknown and would require further study. 
This work suggests that high MSI1 expression levels in neural precursors could be a 
key contributor to the fetal neurotropism exhibited by ZIKV (2, 10, 37) (Fig. S13). Intriguingly, 
MSI1 is also highly expressed in the retina and testis, other tissues deemed vulnerable to 
ZIKV infection (38-41). While our study provides new insight into the potential pathogenic 

mechanisms of ZIKV, further work will be required to determine if the modification or 
interference of the MSI1-ZIKV interaction results in neuronal attenuation of ZIKV. 	




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Fig. 1. MSI1 interacts directly with the ZIKV RNA genome.  
A)  Schematic diagram of PE243 ZIKV containing three putative MSI1 binding sites in its 
3’UTR. Sites shared with MR766 are red, site unique to PE243 is blue.  
B)  RNA pull-down assays performed with the 3’UTR of PE243. Increasing concentrations of 
in vitro transcribed biotinylated PE243 RNA were incubated with U-251 cell extracts and 
RNA-protein complexes were captured on streptavidin beads. Representative western 
blots were probed with antibodies against MSI1 and the RNA binding proteins, Musashi-
2 (MSI2) and hnRNP Q/R. Corresponding protein and RNA inputs are shown on right.  
C)  RNA pull-down assays performed with the wild type (WT) or triple mutant (Δ123) 3’UTR 
of PE243. Note that PE243-3’UTR_Δ123 lacks all three MSI1 binding sites depicted in 
Fig. 1A (see Fig. S1C for further details). Increasing concentrations of in vitro transcribed 
biotinylated RNA were incubated with U-251 cell extracts and RNA-protein complexes 
were captured on streptavidin beads. Representative western blots probed with antibody 
against MSI1 are shown together with corresponding protein and RNA inputs.  
D)  Densitometric analysis of MSI1 levels from western blots of RNA pull-down assays, an 
example for which is shown in Fig. 1C. The amount of MSI1 precipitated by PE243-
3’UTR_Δ123 is expressed as a percentage of MSI1 precipitated by the same 
concentration of PE243-3’UTR_WT. n=3 biological replicates. P-values were obtained 
from Student’s t-test, unpaired, two-tailed: * p<0.05, *** p<0.0005. Bar charts depict 
mean±s.e.m.  
E)  CLIP analysis from mock- or ZIKV PE243-infected U-251 cells. Western blot shows 
immunoprecipitatations (IP) by rabbit IgG and MSI1 antibodies from mock and PE243-
infected U-251 cells following UV crosslinking. Input (5%) represents whole cell extract. 
Western blot was probed with MSI1 antibody. Graph below shows qPCR performed on 
bound RNA from IP. CLIP values are presented as a percentage of input following 
subtraction of the IgG background. GAPDH serves as negative control. n=3 biological 
replicates. Note that a primer pair against 9519-9681 bp of ZIKV genome was used in 
these qPCRs (Table S4). 
F)  Immunofluorescence of mock- or PE243-infected U-251 cells. MSI1 (green) and dsRNA 
(red) signals are detected by confocal microscopy. DNA is detected by Hoechst stain 
(blue). Framed area is shown at higher magnification below.  
G)  Immunofluorescence of a PE243-infected U-251 cell. MSI1 (green) and dsRNA (red) 
signals are detected by STED super resolution microscopy. Outlines of the cell and 
nucleus are indicated in white and blue, respectively. Framed area is shown at higher 
magnification. 
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Fig. 2. MSI1 is required for effective replication of ZIKV. 
A) Graph on left depicts viral RNA copies in control siRNA- (siCon) and MSI1 siRNA 
(siMSI1)-treated SK-N-BE2c and U-251 cells following infection with PE243 (MOI: 1 
FFU/cell, 72h). Graph on right shows viral RNA copies in MSI1 siRNA-treated H9-derived 
neural stem cells (NSC) following infection with PE243 (MOI: 1 FFU/cell, 48h). Note that in 
all viral replication assays ZIKV was quantified by TaqMan assay as described in 
Materials and Methods. n=3 biological replicates. P-values were obtained from Student’s 
t-test, unpaired, two-tailed: * p<0.05, ** p<0.005, not significant (n.s.).  
B) Representative western blots of cell lines treated with control and MSI1 siRNAs from Fig. 
2A. Blots were probed with antibodies against MSI1 or p150 as loading control.  
C) Location of the guide RNAs used for CRISPR/Cas9-mediated editing of the MSI1 locus in 
U-251 cells. For further details see text and Fig. S2. Western blots of parental, control, 
KO1 and KO2 cell lines probed with antibodies against N- and C-termini of MSI1 (NT or 
CT) and MSI2. p150 serves as loading control.   
D) Kinetics of PE243 viral RNA copies following infection in U-251 cells of different 
genotypes at the indicated time points. Note that cell death precluded collection of RNA 
from parental and control cells at 72h (MOI: 3 FFU/cell, 72h).   
E) Confocal microscopy images of PE243-infected control and KO1 U-251 cells 
immunostained with antibodies against dsRNA (green) and Hoechst DNA stain (red) 
following mock or PE243 infection (MOI: 3 FFU/cell, 48h). Graph on top shows 
percentage of cells containing dsRNA signal, whereas box plot on bottom depicts total 
dsRNA staining volume per cell. Note that only cells with detectable dsRNA signal were 
included in the latter analysis. Boxes: 25th to 75th percentile; whiskers: 5-95% range; line: 
median. P-value represents Student’s t-test, unpaired, two-tailed: **** p<0.0001.  
F) Viral RNA copies in U-251 cells of different genotypes following infection with MR766 
(MOI: 3 FFU/cell, 48 h). n=3 biological replicates. P-values were obtained from Student’s 
t-test, unpaired, two-tailed: * p<0.05, ** p<0.005, not significant (n.s.).  
G) Virus-binding assays performed under conditions that prevent internalisation. PE243 
infection was performed in U-251 cells of different genotypes (MOI: 3 FFU/cell, 1h). n=3 
biological replicates. P-values were obtained from Student’s t-test, unpaired, two-tailed: * 
p<0.05, ** p<0.005, not significant (n.s.). Bar charts depict mean±s.e.m.  
H) Pseudotyped particle infectivity assay in U-251 cells of different genotypes. HIV (pNL4-
3.luc.R-E-) or MoMLV pseudotyped virus expressing a luciferase reporter, with either 
PE243 ZIKV, VSVg or a negative control envelope used to determine viral entry events. 
n=3 biological replicates. P-values were obtained from Student’s t-test, unpaired, two-
tailed: * p<0.05, ** p<0.005, not significant (n.s.). Bar charts depict mean±s.e.m. 

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Fig. 3. MSI1 is enriched in neural progenitors, regulates Microcephalin (MCPH1) 
expression and is mutated in MCPH patients. 
A) Immunohistochemistry of human embryonic brain at post conception week (pcw) 10 and 
12. Tissue sections stained with antibodies against MSI1 (red) combined with neuron-
specific β-III tubulin (green), or the apical neural progenitor marker Nestin (green). DNA is 
detected by DAPI (blue). Note that MSI1 is enriched in neural progenitors at the 
ventricular and subventricular zones (VZ and SVZ), but is absent from the cortical plate 
(CP).  
B) MSI1 CLIP from U-251 cells with genotypes as indicated. CLIP was performed with rabbit 
IgG or MSI1 antibodies. Graphs show qPCRs of bound transcripts. n=3 biological 
replicates. P-values were obtained from Student’s t-test, unpaired, two-tailed: * p<0.05, ** 
p<0.005, not significant (n.s).  
C) RNA EMSA analysis to detect binding between MCPH1_L 3’UTR and purified GST-MSI1 
recombinant protein. Coomassie staining of corresponding purified proteins is shown 
below.  
D) Western blots of parental, control, KO1 and KO2 cell lines. Blots were probed with 
antibodies as indicated. p150 serves as loading control.  
E) Western blots of whole cell lysates from parent-of-patient- and patient-derived primary 
lymphocytes. Blots were probed with antibodies as indicated. MSI1 levels are unchanged. 
F) MSI1 RIP from mock- and ZIKV-infected U-251 cells (MOI: 1 FFU/cell). Rabbit IgG or 
MSI1 antibodies were used for immunoprecipitation. Input corresponds to 10% of whole 
cell extract. Western blot was probed with MSI1 antibody. Graphs below show amounts of 
bound RNAs including ZIKV genome and endogenous target transcripts. RIP values are 
presented as a percentage of input following subtraction of the IgG background. MR766 
and PE243 were quantitated by TaqMan assay, whereas endogenous transcripts with 
SYBR qPCR. Bar charts depict mean±s.e.m. n=3 biological replicates. P-values were 
obtained from Student’s t-test, unpaired, two-tailed: * p<0.05, ** p<0.005, not significant 
(n.s.).  
G) Western blots of PE243-infected U-251 cells. (MOI: 1 FFU/cell, 72h). Blots were probed 
with antibodies as indicated. α-tubulin serves as loading control. Note that MSI1 positively 
regulates MCPH1 and CDK6, and negatively regulates NUMB and p21 protein levels.  
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Fig. 4. The A184V MCPH mutation disrupts RNA binding by MSI1 and impairs the 
ability of MSI1 to drive ZIKV replication.  
A) Structural model of MSI1 (blue) and HRP1/RNA complex (grey/orange) predicts that the 
A184V mutation impairs the interaction with RNA due to a steric clash.  
B) Western blots of cell lines stably expressing WT or A184V MSI1 transgenes. Note that cell 
lines were derived from either KO1 or KO2 cells as specified. Blots were probed with 
antibodies as indicated. p150 serves as loading control. Graph shows signal intensities of 
each protein normalized to parental cells.   
C) MSI1 RIP from U-251 cells with genotypes as indicated. Rabbit IgG or MSI1 antibodies 
were used for immunoprecipitation. Input corresponds to 10% of whole cell extract. 
Western blot was probed with MSI1 antibody. Graphs below show qPCRs of bound 
transcripts. n=3 biological replicates. P-values were obtained from Student’s t-test, 
unpaired, two-tailed: * p<0.05, ** p<0.005, not significant (n.s).  
D) Quantification of viral RNA copies in U-251 cells with the indicated genotypes following 
infection with PE243 (MOI: 3 FFU/cell, 48h). n=3 biological replicates. P-values were 
obtained from Student’s t-test, unpaired, two-tailed: ** p<0.005, not significant (n.s).  
E) Changes in survival of U-251 cells with different genotypes following infection with PE243 
(MOI: 3 FFU/cell, 48h). n=3 biological replicates. P-values were obtained from Student’s t-
test, unpaired, two-tailed: * p<0.05, ** p<0.005, not significant (n.s). 
F) ZIKV infection of HEK293T cells as measured by FACS analysis of flavivirus protein E. 
FACS was performed on control, MsiWT or MsiAV transgene-expressing cells following 
infection with PE243 (MOI: 1 FFU/cell, 48h). n=2 biological replicates. Bar charts depict 
mean±s.e.m. 
G) Changes in survival of control, MsiWT or MsiAV transgene-expressing HEK293T cells 
following infection with PE243 (MOI: 3 FFU/cell, 48h). n=3 biological replicates, and P-
values were obtained from Student’s t-test, unpaired, two-tailed: * p<0.05, ** p<0.005, not 
significant (n.s). 
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Materials and Methods 
 
Clinical details 
The index case was the first born to healthy Turkish parents, who were first cousins (see Fig. 
S8). He was noted to be microcephalic at birth, but had no significant growth or health 
problems in his first year. At four years of age he was assessed to have mild cognitive delay, 
but had no motor delay nor fits and had a normal neurological examination. At that age his 
height was 95.3cm (-3 standard deviations (SDS)) and OFC 43.5 (-4 SDS for age and sex). 
With the exception of microcephaly he had no dysmorphic features, was in good health, did 
not suffer from excess infections and had a normal tolerance to sunlight, vision and hearing. 
He was seen again at age 8, when it was clear he had definite mild/moderate developmental 
delay. He attended a special school. His height was 117cm (-3 SDS) and OFC 45 (-5 SDS). 
On investigation he had no structural chromosomal anomalies, but cytogenetic spreads did 
show increased premature chromosome condensation (PCC). The patient had a significantly 
increased number of cells exhibiting PCC (14%) with respect to three control patients (6%). 
His youngest sister was seen at age of 7 months and had been noted to be microcephalic at 
birth. At 7 months her psychomotor development seemed normal. Her length was 63 cm (-2 
SDS) and OFC 37.4 (-4 SDS). Both parents have normal intelligence, a normal height (both 
163cm, -2 SDS for the father and 0 SD for the mother) and head circumferences; father 53cm 
(-1 SD) and mother 52 (-2 SDS). There is a healthy second sister with normal development 
and growth parameters. We concluded that the phenotype was inherited as an autosomal 
recessive trait because i) the male and female children were similarly affected, ii) a third 
sibling was unaffected, and iii) both parents were unaffected. The family gave informed 
consent to enter the study, which was approved by the National Research Ethics Service 
Committee, East of England - Cambridge Central, UK (C.G. Woods, REC 05/Q0108/402). 
 
Molecular genetics 
Standard methods were used to extract DNA from the two affected children and their parents. 
Given the phenotype of primary microcephaly, premature chromosome condensation and 
possible short stature, the MCPH1 gene was sequenced (28, 29). Surprisingly, no mutations 
were found and examination of the MCPH1 genotypes showed that they had discordant 
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heterozygosity for MCPH1 (subsequent exome sequencing confirmed this finding). Taken 
together these results eliminated MCPH1 as a cause of this recessive phenotype. As the 
phenotype was recessive and the parents consanguineous, we performed homozygosity 
analysis seeking concordant homozygous segments of > 3cM(42). Autozygosity mapping is 
likely to identify the regions of the genome containing recessive gene mutations in 
consanguineous pedigrees (43, 44). Genomic DNA from the affected male was hybridized to 
the Affymetrix GeneChip® Human Mapping 250 K Nsp Array. Results of the alleles present 
at each SNP for each individual were generated using Affymetrix software. Regions of shared 
allele-concordant homozygosity were sought using CNAG2.0 (http://www.genome.umin.jp/ 
and (45)), and further analysed with ExcludeAR(42). This revealed fourteen regions of 
conserved homozygosity totaling 374Mb, a tenth of the genome - as expected for the child of 
first cousins (46), (see Table S1). Next, exome sequencing was performed on the affected 
male and female using the SureSelect Human All Exon 50Mb Kit (Agilent Technologies UK, 
Cat. No G3370A), enabling targeted capture of 50Mb sequence of exonic regions and non-
coding RNAs in the human genome. Sequencing was performed with the SOLiD™4 System 
(Applied Biosystems) with 50bp fragment reads, to generate 4.3Gb of sequence achieving 
83% of bases coverage by >10 reads (sufficient for the detection of homozygous mutations) 
of the mappable targeted 50Mb exome. Initially, the raw sequencing reads were mapped to 
the GRCh37 reference human genome and changes compared to this reference sequence 
identified (47). First, we checked all reported MCPH genes, but found no homozygous or 
potential compound heterozygous mutations. Next, we focused our analyses on non-
synonymous coding, nonsense, splice site variants and indels (insertions–deletions) involving 
exons (1542 before further filtering analysis). We filtered against: (i) known variations where 
the rare allele frequency was >1% (derived from dbSNP and 1000 Genomes); (ii) high (all 
mammals) or complete evolutionary conservation of the encoded amino acid, by use of the 
Human Genome Browser full conservation track; (iii) examination of the sequence reads 
containing potential mutations using the Integrated Genome Viewer (which shows 
misaligned, poorly sequenced and recurrent artefact changes); (iv) presence within a 
homozygous region and (v) known phenotype of recessive gene mutations. We found four 
homozygous mutations (see Table S2), of which, three were not expressed in the foetal/ 
embryonic brain of humans or mice (Genepaint: http://www.genepaint.org/Frameset.html and 
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Brainspan Atlas of the Developing Human Brain (48)). The remaining mutation was on 
chromosome 12 at position 120794806G>A. This causes a missense mutation c.551C>T in 
MSI1 (MUSASHI-1) changing a GCT codon to GTT and resulting in p.Ala184Val, predicted 
to be potentially pathogenic in PolyPhen and SIFT (see Table S2). The p.(Ala184Val) 
mutation has not been reported in the 1000 Genomes project, EVS or ExAC 
(http://browser.1000genomes.org/index.html (49); http://evs.gs.washington.edu/EVS/#tabs-7 
(50); and http://exac.broadinstitute.org). The mutation segregated as expected in the affected 
children and their parents. MSI1 Ala184 is present in all reported vertebrates; in D. 
melanogaster Musashi Ala184 was equivalent to Ala337 and in C. elegans Ala209. We found 
no further bi-allelic or homozygous MSI1 mutations in our own cohort, and those of 
colleagues, of approximately 100 MCPH families, which had no mutations in known MCPH 
genes. 
 
Cell lines and reagents 
U-251 MG, Vero, HEK293T cells were maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% FBS, 1% penicillin/streptomycin, 1% non-essential amino acids 
and 1% L-glutamine. H9-derived neural stem cells (hNSC) were obtained from Invitrogen 
(Cat. No. N7800-200) and were cultured following the manufacturer’s instructions. SK-N-
BE2c cells were maintained in DMEM:F12 media containing 10% FBS, 1% 
penicillin/streptomycin and 1% L-glutamine.  All cell lines were tested to be mycoplasma 
free. C6/36 insect cells were supplied by A. Kohl (Centre for Virus Research, University of 
Glasgow) and were maintained in Leibowitz-15 (L-15) media containing 10% FBS, 1% 
penicillin/streptomycin, 1% L-glutamine, 1% non-essential amino acids, and 20% tryptose 
phosphate broth (TPB, Sigma).  
 
Genome editing of the MSI1 locus by CRISPR-Cas9 
The strategy and exons targeted with respective guides to generate MSI1 knockout in U-251 
cells are depicted Fig. S2. Briefly, guides were generated as single stranded oligos and 
annealed to be cloned into Bbs1 linearised pSpCas9(BB)-2A-Puro (pX459). Positive clones 
containing guides were identified by sequencing and 0.5 g of the guide RNA vectors were 
transfected into a single well of 12 well plate. Twenty-four hours post transfection, 2.5 ]g/ml 
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puromycin was added and left for 48 h. The surviving cells were plated onto a 15cm plate and 
single colonies were picked after 2 weeks. Clones were expanded and screened using western 
blot analysis using both the N- and the C-terminal MSI1 antibodies to detect complete 
knockout. Positive knockout clones were then genotyped to confirm biallelic modification of 
the MSI1 locus. 
 
Antibodies  
Primary antibodies used in this study are: MSI1 (rabbit - ab21628: Abcam; rat - D270-3: 
MBL), MCPH1 (HPA008238, Cambridge Bioscience), CDK6 (Cell Signaling), NUMB 
(N6539: Sigma), p150 (612708: BD Bioscience), MSI2 (107701AP, Proteintech), hnRNP 
Q/R (Cell Signaling), PABP (Abcam, ab21060), Lamin B1 (Cell Signaling), Nestin (Abcam, 
ab22035), -tubulin (Sigma), -tubulin III (Abcam, ab18207), dsRNA-J2 (Scicons), p21 
(2936, CST; ab109199, Abcam), flavivirus envelope E protein (D1-4G2-4-15, Absolute 
antibodies, Millipore). DNA was stained with Hoechst 33258 (Sigma-Aldrich) or DAPI. 
Isotype-matched Alexa-conjugated secondary antibodies (Thermo Fischer Scientific) were 
used for immunofluorescence and secondary antibodies conjugated to HRP (Amersham) or 
IRDye (LI-COR) were used for immunoblotting. For detection of MSI1 (rat), goat anti-rat 
HRP (Abcam, 97057) was used. 
 
Western blotting and quantitation 
U-251 cell pellets were lysed in modified TNN buffer (25 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1.5 mM EDTA, 0.5% NP-40, 0.1% Triton-X100, and protease inhibitor cocktail 
[Sigma-Aldrich]) on ice for 15 min. Whole cell extracts were obtained by pelleting (16,000 g 
for 15 min at 4°C) and discarding the insoluble debris. H9-hNSC cells were lysed in NP40 
lysis buffer (50mM Tris-HCl, pH 8, 125mM NaCl, 1% NP-40, 2mM EDTA, 1mM 
phenylmethylsulphonyl fluoride and protease inhibitor cocktail (Roche) and incubated on ice 
for 25min. 
Extracts were separated by SDS-PAGE using 4-12% Bis-Tris NuPAGE gels (Invitrogen) and 
blotted onto nitrocellulose membrane using iBlot1.0 (Invitrogen). Blots were incubated with 
primary antibodies at 1 μg/ml final concentration. Secondary antibodies conjugated to HRP 
(Amersham) were used at 1:5,000 dilution. Antibody binding was detected using an ECL 
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system (Lumilight: Roche; Femto: Pierce) according to the manufacturer’s instructions. 
Densitometric analysis of Western blots was performed by ImageJ. For LiCOR, blots were 
processed as above and probed with mouse or rabbit specific IRDye 800 (LiCOR) and 
acquired using Odyssey CLx. Obtained fluorescent images were quantitated using 
Imagestudio.  
 
Plasmid transfections and RNA interference 
Cells were seeded the day before to achieve 60% confluency on the day of transfection. To 
generate stable cell lines expressing MSI1 transgene, cells were co-transfected with pCDNA-
Msi1WT or pCDNA-Msi1A184V and pBSK-PuromycinR in HEK293 and pBSK-
BlasticidinR in U-251 cells in a single well of 6 well plate. 24 h post transfection, cells were 
split into 15 cm plates with 2.5 ]g/ml puromycin or 8 ]g/ml blasticidin. After 2 weeks, single 
colonies were picked and expanded. Positive clones were selected based on MSI1 reactivity 
on western blot, with parental U-251 cells serving as positive control. In case of siRNAs in 
U-251 cells, 25nM siRNA per well was transfected in a 24-well plate using Viromer green 
(Lipocalyx) as recommended by the manufacturer. 6h after transfection, the medium was 
changed. Cells were processed 72h after transfection and analysed by western blot to check 
the knock-down efficiency. siRNAs used in this study were MSI1 (SR302970; Origene), 
MCPH1 (SR312491; Origene), universal scrambled negative control (SR30004; Origene). 
For siRNA treatments followed by viral infections, 25nM MSI1 siRNA was transfected using 
RNAiMax following manufacturer’s instructions (Invitrogen). hNSC cells were seeded in 6 
or 24 well and transfected with 1μM of control non targeting pool (Thermo Fisher, D-
001910-10-20) or MSI1 Accell siRNA smart pool (Thermo Fisher, E-011338-00) according 
to the manufacturer’s instructions. After 3 days of transfection, Accell medium was replaced 
with hNSC medium and the cells were subjected to viral infections for additional 2 days 
before collecting RNA and proteins.   
 
ZIKV 5’/3’ UTR luciferase reporter assay 
Firefly luciferase reporter genes flanked by the 5’UTR and 3’UTR sequences of the PE243 
strain of Zika virus and a T7 promoter sequence were synthesized by Integrated DNA 
Technologies. 5’ XbaI and 3’ HindIII restriction enzyme sites were included to facilitate 
cloning into pUC57. Reporter RNAs were produced by in vitro T7 transcription of 
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HindIII linearised plasmids and capped using the ScriptCap system (Cellscript). HEK293T 
cells were initially transfected with Lipofectamine 2000 (Thermo Fisher) in 6-well plates 
with 1.5 ]g total nucleic acid comprised of pcDNA Msi1 and/or empty pcDNA as indicated 
in Fig. S4. Following expression for 24h, cells were re-seeded in 96 well plates and 
subsequently transfected with 145ng of PE243 capped firefly luciferase reporter mRNA and 
5ng of pRL-TK Renilla luciferase reporter plasmid (Promega). Cells were incubated for a 
further 24h before luciferase production was assayed.  
 
Polysome fractionation 
Polysome fractionation from parental or MSI1 KO2 U-251 cells was performed as described 
in (51). Briefly, cells were washed with PBS containing cycloheximide (CHX) and lysed in 
hypotonic buffer (5 mM Tris-HCl (pH 7.5), 2.5 mM MgCl2, 1.5 mM KCl and 1x protease 
inhibitor cocktail (EDTA-free, 50 ]g CHX, 1]M DTT, 100 units of RNaseOUT (Thermo 
Fisher Scientific), 0.5% Triton X-100 and 0.5% sodium deoxycholate). Clarified lysates 
(OD260 of 15) were loaded onto a continuous sucrose gradient (5-50% containing CHX) and 
subjected to ultracentrifugation. Fractions were collected and UV absorbance profiles 
recorded. 1 ml of trizol was added to 300]l fraction and processed for mRNA isolation. RNA 
from each of the 12 fractions was reverse transcribed using SuperScript III First-Strand 
Synthesis SuperMix and qPCR performed to determine distributions of GAPDH and 
MCPH1_L. For protein analysis 50]l fractions were subjected to TCA precipitation and 
processed for western blotting as described before.  
 
Plasmid mutagenesis 
pJET1.2 vector containing 3’-UTR of Zika virus PE243 (428bp) were subjected to site-
directed mutagenesis following the standard sense-antisense method using Phusion DNA 
polymerase (NEB) in GC buffer with 2% DMSO followed by DpnI (NEB) digestion. The 
primers used for the mutagenesis are listed in Table S4. 
 
Cell cycle analysis 
The U-251 control and MSI1 knock-out cells were dissociated by trypsin digestion, washed 
with PBS and fixed with cold 70% ethanol for 30 min on ice. The cells were then washed 
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twice with PBS, incubated in PBS containing RNaseA (100]g/ml Life Technologies) for 
30min at 37°C followed by staining with propidium iodide (20]g/ml, Life Technologies) in 
PBS on ice in the dark for 30min. DNA content was analysed by FACS Calibur (Beckton 
Dickinson) using BD CellQuest Pro Software V6. Cell cycle analysis was performed using 
FlowJo software V9 (TreeStar Inc).  
 
Wound healing assay 
Wound healing assay for U-251 control and MSI1 knock-out cells was performed in 
triplicates on 24-well (Essen Imagelock) plates seeded with 300,000 cells/well and imaged 
the second day onwards. The cell migration was followed for 78h using IncuCyte ZOOM 
(Essen Bioscience), making measurements in triplicate every 3h. The IncuCyte ZOOM 
version 2016B software was used to capture and analyse the images. 
 
Zika virus genesis and infection 
Zika virus stocks were generated by transfecting PE243 RNA (supplied by A. Kohl, Centre 
for Virus Research, University of Glasgow, Lindomar J. Pena and Rafael Oliveira de Freitas 
França, Fiocruz Recife, Pernambuco, Brazil) and MR766 RNA (PHE Culture Collections) 
into C6/36 cells using Lipofectamine 2000 (Life Technologies). Viral supernatants were 
collected 72h post-transfection and at subsequent 24h intervals. Virus stocks were pooled, 
aliquoted and stored at -80oC. Viral titres were determined by immunofocal assays with serial 
viral dilutions onto Vero cells. Following 72h incubation, cells were fixed and stained for 
Zika flavivirus E-protein, which was then quantified by counting fluorescent foci 
(immunofluorescence described below) to determine focus-forming units per mL (FFU/mL). 
Zika viral RNA loads were also determined by qPCR (as described below). For infections, 
various cell lines (treated or untreated, as described in the text) were inoculated with virus at 
defined MOI (FFU/cell), incubated for 6h, then washed thoroughly with PBS, before media 
was replaced and incubated for a further 48 or 72h as stated. Viral cells or supernatants were 
then harvested for either RNA extraction or imaging. For TCID50 assay, U-251 control and 
MsiKO cells were infected with PE243 virus at an MOI of 0.01 and 0.001 FFU/cell. 72 hours 
post-infection, the cultures were frozen and thawed, the supernatant clarified and the virus 
yield determined by TCID50 using the Reed–Muench method in Vero cells by staining for 
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the presence of viral antigen. 
 
Zika pseudoparticle entry assay  
Pseudoparticles were generated by transfecting HEK293T cells with plasmids encoding HIV-
1 provirus expressing luciferase (pNL4-3-Luc-R-E-), or Moloney murine leukemia virus 
(MoMLV) with a luciferase reporter (pTG126) with either ZIKV-Env, vesicular stomatitis 
virus G (VSVg), or a no-envelope (NE) control as previously reported (52). Supernatants 
were harvested 48h post transfection and clarified by centrifugation. Virus containing 
medium was added to target cells plated in 96-well plates, incubated for 4h, before cells were 
washed and media replaced. 48h post-infection, media was removed, cells lysed and 
luciferase activity measured. ZIKVpp infectivity was calculated by expressing the ZIKV or 
VSVg luciferase signal (relative light units, RLU) relative to the NE control. 
 
Virus Binding Assay 
U-251 parental, control and Msi1-KO cells were incubated on ice for 30 mins, then 
equivalent MOI of PE243 virus was added to the cells, while still on ice. Cells were then 
incubated for 1h, before washing 5 times with PBS, then lysing and extracting RNA from 
cells. RNA loads were then assessed by qPCR using the Genesig Zika qPCR kit 
(PrimerDesign).  
 
Flu virus genesis and infection 
Human influenza virus A/Puerto Rico/8/34 (H1N1) strain, designated as PR8, was provided 
by Paul Digard (University of Edinburgh), amplified in A549 cells, then titered on MDCK 
cells. For infections, equal virus titres were treated with trypsin (0.1%) for 5 mins, then added 
to target cells for 4h. Virus was then removed and the cells incubated for a further 48h before 
RNA was extracted and quantified using Genesig H1N1 Influenza qPCR kit (PrimerDesign).  
 
Zika RNA quantification 
To quantify viral replication, RNA was extracted from cells using the GenElute Mammalian 
RNA Miniprep Kit (Roche) following the manufacturer’s protocol. Total RNA was then 
quantified by NanoDrop 1000 quantification (Thermo Fisher Scientific). qPCR was carried 
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out using TaqMan® chemistry, with a commercial quantification kit (Genesig Standard Zika 
Virus Quantification Kit, PrimerDesign), using One-Step 2X qPCR Reagent (PrimerDesign). 
 
Flow cytometry: quantification of flavivirus E protein  
For flow cytometry, infected or control cells were fixed in 4% paraformaldehyde for 20 mins, 
then washed thoroughly, followed by blocking in PBS containing 0.5% bovine serum 
albumin (BSA), 0.1% Triton X-100 (PBST). Cells were stained overnight at 4ºC, using 4G2 
anti-flavivirus antibody in PBST plus sodium azide, followed by isotype-matched Alexa 488-
conjugated mouse IgG antibody (Invitrogen) for 1h at room temperature. Cells were then 
analysed on a FACSCalibur (BD Biosciences), counting 20,000 cells of each condition in 
duplicate. Results were then analyzed with FlowJo® Flow Cytometry software. 
 
Immunofluorescence analysis 
For fluorescent imaging of flaviviral particles and dsRNA, cells were fixed using 1% 
formaldehyde for 10 min, then washed thoroughly with PBS and permeabilised with PBS 
containing 0.5% Triton-X-100 for 10 min, followed by blocking in PBS containing 0.5% 
bovine serum albumin (BSA), 0.1% Triton X-100 (PBST). Cells were stained overnight at 
4ºC, using 4G2 anti-flavivirus antibody or dsRNA-J2 antibody in BSA-PBST, followed by 
isotype-matched Alexa 488-conjugated mouse IgG antibody (Invitrogen) for 1h at room 
temperature. To analyse premature chromatin condensation, cells were fixed in ice-cold 
methanol for 5 min, followed by washing with 0.1% Tween containing 1XPBS. Cells were 
then blocked in PBS containing 5% BSA for 10 min and subjected to overnight staining with 
Lamin B1 antibody (1:1000, Cell Signalling) at 4ºC. Isotype specific secondary antibody was 
added for an hour at 37ºC and DNA was stained with DAPI or Hoescht. Images were 
acquired on a Leica SP8 STED-equipped microscope in confocal or STED modes. Image 
quantification was performed by Volocity 6.3 (Perkin Elmer). dsRNA-positive staining 
volumes were selected by intensity thresholding. Identical settings were used on all cells 
regardless of genotype or treatment.  
 
Immunohistochemistry of fetal brain  
Human paraffin-embedded brain sections (10pcw and 12pcw), fixed with 4% 
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paraformaldehyde were obtained from the MRC-Wellcome Trust Human Developmental 
Biology Resource. Sections were boiled for 10 min in 10 mM sodium citrate buffer (pH 6.0) 
and permeabilized in 0.3% Triton-X-100 for 30 min. Sections were blocked in 3% BSA and 
0.3% Triton-X-100, and incubated with primary antibodies overnight in blocking buffer.  
Alexa-Fluor-conjugated secondary antibodies (Invitrogen) were added on the sections for 1 
hour at room temperature, DAPI stained (Invitrogen) for 3 minutes and finally mounted onto 
ProLong Gold antifade reagent (Invitrogen). Sections were visualised on both a LSM880 
Confocal Microscope with AiryScan, and a Zeiss AxioImager Z2 Upright Wide-field 
Microscope. Primary antibodies and their concentrations used on tissue sections are rat anti-
MSI1 at (1:200), anti-beta III tubulin antibody (1:2000) and anti-Nestin antibody (1:200). 
 
Cell viability assay 
Cell viability was determined using the CellTitre Blue™ Kit (Promega), following 
manufacturer’s instructions. Briefly, cells were seeded at equal densities and infected for 48h 
with PE243. Virus was removed, cells washed and 1X CellTitre Blue reagent was then added 
to the cells and then the plates were incubated for a further 4h at 37ºC. Absorbance was then 
measured at 570 nm, and viability compared to uninfected control cells.  
 
RNA immunoprecipitation (RIP) 
RIP was performed from the parental and clonal U-251 cells, or PE243/ MR766/mock- 
infected U-251 cells using rabbit IgG (Sigma) and MSI1 (Abcam, ab21628) antibodies as 
previously reported (53). Quality of immunoprecipitations was assessed by immunoblot 
analysis with rat MSI1 antibody (MBL, D270-3). Briefly, 1.5 mg of total protein lysates were 
incubated with 8]g of for 2h at 4°C, followed by addition of Protein A/G beads (Pierce) for  a 
further 2h at 4°C. Beads were washed 3 times (5min each) with lysis buffer and RNA 
extracted by addition of 1ml TRIzol (Life Technologies) to the beads. 10% of the lysate was 
used as input RNA pellet obtained after phenol chloroform extraction and ethanol 
precipitation. Finally, RNA was dissolved in 60]l of RNase-free water (Life Technologies). 
Power SYBR Green RNA-to-CT 1-Step Kit (Life Technologies) was used to set up for 
qPCR. Primers used are listed in Table S4. To detect ZIKV in RIP (Fig. 4H) qPCR was 
carried out using TaqMan® chemistry, with a commercial quantification kit (Genesig 
Standard Zika Virus Quantification Kit), using One-Step 2X qPCR Reagent (PrimerDesign). 
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Cross-Linking Immunoprecipitation and qPCR (CLIP-qPCR) 
CLIP was performed as described previously (54) with slight modifications. The U-251 cells 
were crosslinked with 300mJ/cm2 of UVA (365nm) on ice using Stratalinker device. 
Subsequently lysates were subjected to partial RNaseI digestion (Thermo Fischer Scientific, 
AM2295, 10μl of 1:500 dilution per 1ml of cell lysate) for 3 min at 37°C and verified on 
agarose gel. This lysate was incubated with MSI1 coated Protein G Dynabeads (Life 
Technologies). Efficiency of immunoprecipitations was verified by western blot analysis. 
Beads were then washed in NP40 lysis buffer and DNaseI (20 U, Promega) was added for 15 
min at 37°C following addition of 0.1% SDS and 0.5 mg/ml Proteinase K (Thermo Fischer 
Scientific) for 15 min at 55°C. The supernatant was collected and RNA was extracted using 
phenol/chloroform extraction and ethanol precipitation. Finally, RNA was dissolved in 15μl 
of RNase free water and qPCR was performed using Power SYBR Green RNA-to-CT 1-Step 
Kit (Life Technologies). Primers are listed in Table S4.  
 
Electrophoretic mobility shift assays (EMSA) 
MCPH1 (long) 3’UTR (NM_001322042.1) was amplified from U-251 cDNA and cloned in 
pJET1.2 vector, linearised with Xba1, purified and 1g was used as template for in vitro 
transcription with 10X biotinylation mix (Roche) using T7 polymerase (NEB). Biotinylated 
RNA was recovered by phenol:chloroform:isoamyl alcohol extraction followed by ethanol 
precipitation. Resulting RNA pellet was resuspended in 50l DEPC water and concentration 
estimated with nanodrop. Approximately 2 nM biotinylated RNA was mixed with 1g of 
GST or GST-MSI1 and EMSA performed using LightShift Chemiluminescence EMSA kit 
(Pierce). The reaction mixes were then run on a 6% PAGE gel and transferred on to a nylon 
membrane. The transferred complexes were UV crosslinked at 120 mJ/cm2 for 45 seconds, 
blocked and probed with streptavidin HRP. 
 
In vitro–biotinylated RNA pulldown 
5g of the wild type and mutant PE243 3’UTRs in pJet1.2 vector were linearised and 
subjected to in vitro transcription using T7 RNA polymerase buffer, T7 RNA polymerase 
(20U, Thermo Fisher Scientific, 18033-019), 8mM GTP (GE Healthcare), 5mM ATP (GE 
Healthcare), 5mM CTP (GE Healthcare), 1.3mM UTP (GE Healthcare), 0.7mM Bio-16-UTP 
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(Epicentre), 5mM DTT (Sigma), 20mM MgCl2, 80U/ml RNaseOUT (Thermo Fisher 
Scientific).  The mixture was incubated for 3h at 37°C and EDTA (60mM) was added and 
precipitated overnight at -20°C. After centrifugation at 14000g for 30 min, the precipitate was 
dissolved in 50μl of water and cleaned with Bio-Spin 30 columns (Bio-Rad, 732-6231). 
Following DNaseI treatment (Promega) for 15 min at 37°C the reaction was cleaned once 
again with Bio-Spin 30 columns and RNA was precipitated overnight at -20°C and dissolved 
in 30μl of RNase free water. Purity of RNA was analysed on agarose gel using RNA Gel 
Loading Dye (2X, Thermo Fisher Scientific, R0641) after denaturation at 72°C for 10 min. 
For the pulldown, three hundred micrograms of total protein from U-251 cells was used (lysis 
buffer: 25mM Tris HCL, pH 7.4, 150mM KCl, 5mM EDTA, 5mM MgCl2, 1% NP40, 
0.5mM DTT, protease inhibitor cocktail (Roche), 100U/ml RNAse OUT) and first precleread 
with magnetic MyOne Streptavidin T1 Beads (Thermo Fischer Scientific, 65601). The 
precleared lysate was diluted 2x in lysis buffer and supplemented with tRNA (0.1μg/μl, 
Thermo Fisher Scientific) and incubated with different concentrations of biotinylated RNA 
(1-20 pmol) for 2h  at 4°C. Biotinylated RNA was previously heated up to 60°C for 5 min 
and slowly cooled down to room temperature. Subsequently, 40μl of MyOne Streptavidin T1 
Beads were added for an hour and the beads were washed three times with lysis buffer 
containing 300mM KCl. Finally, the beads were resuspended in 50μl of sample buffer (4X, 
Bio-Rad) and reducing agent (20X, Bio-Rad), vortexed and boiled for 5 min at 95°C. After a 
short spin, the supernatant was collected and subjected to western blot analysis. 
 
Statistical analysis and validations 
Statistical significance of data was determined by two tailed t-tests in all experiments using 
R, after Shapiro-Wilk test for normality. P-values for each comparison are indicated in 
corresponding legends. In certain cases Fisher’s exact test was used as indicated in legend. A 
minimum of 3 biological replicates was performed for each experiment, unless otherwise 
stated. All viral infections and qPCR experiments were performed double blind. 
 
Structural modelling 
 
The NMR structure of human MSI1 RNA binding domain 2 in the absence of RNA (PDB 
code 2MSS, residues 110-184) and the crystal structure of S. cerevisiae HRP1/RNA complex 
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(PDB code 2CJK) were used to build a homology model of the MSI1 residues 110-187 in a 
predicted RNA-bound conformation(55). The model was generated using Modeller 9.15 and 
the structure figure was generated using PyMOL (www.pymol.org)(56).    
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Figures and Figure legends 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1. Consensus MSI1 binding sites in the 3’UTR of ZIKV.  
A) Location of consensus MSI1 binding sites in a structural model of ZIKV 3’UTR (adapted 
from (16), http://sergio14.github.io/Flaviviruses_RNA_Structures/Flavivirus-3UTR.svg#1). 
Sites common between MR766 and PE243 are in orange, site unique to PE243 is in blue. 
Note that there are additional putative MSI1 binding sites in the coding region of ZIKV RNA. 
However, a lack of detailed structural information makes it difficult to assess whether these 
map to stem-loop structures. 
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B) Alignment of sequences proximal to MSI1 binding sites in MR766 and PE243. 
C) Mutagenesis of MSI1 binding sites in 3’UTR of PE243. All three MSI1 binding sites were 
mutated as indicated in the 3’UTR of PE243. 
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Fig. S2. Characterisation of MSI1 cDNA sequences from MSI1 KO1 and KO2 U-251 
cells.  
Sanger sequencing reveals differential modifications of the MSI1 alleles in each knockout, 
but all lead to frameshift mutations and hence protein null cell lines (Fig. 2C). PAM sites are 
in pink, guide RNA sequences in blue, whereas base insertions are in italics. Amino acids 
different from wild type sequence are shown in green.  
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Fig. S3. ZIKV replication is impaired in MSI1 KO U-251 cells. 
A) Images show U-251 cells with genotypes as indicated following mock or PE243 infection. 
MOI: 3 FFU/cell, 48h. Cells were stained with an antibody against flavivirus E protein. DNA 
is shown with Hoechst. Scale bar=50]m.  
B) Higher magnification images from same experiment as Fig. S3A. Scale bar=25]m. 
C) Quantification of flavivirus E protein-positive U-251 cells following PE243 infection. 
Genotypes as indicated. MOI: 1 FFU/cell, 24h. Data presented as mean ± s.e.m, n=3. p-
values were obtained from Student t-test, unpaired, two-tailed: * p<0.05, ** p<0.005, not 
significant (n.s.).  
D) U-251 cells were infected with PE243 at an MOI of 0.01 and 0.001 FFU/cell for 72h. 
Infectious virus titer was then quantitated by TCID50 assay and expressed as TCID50 per ml 
values by Reed-Muench method. Genotypes as indicated. Data presented as mean ± s.e.m, 
n=4, p-values were obtained from two-way ANOVA, **p < 0.005. 
 
 
 
 
 
20 
 
 
Fig. S4. MSI1 increases luciferase expression in a ZIKV UTR-dependent manner. 
A) Experimental procedure is depicted in schematics. Following transfection with pcDNA or 
pcDNA-Msi1, Firefly (FLuc) luciferase flanked by the 5’ and 3’UTRs of PE243 ZIKV was 
introduced along with a Renilla luciferase reporter (RLuc) into HEK293T cells. Chart below 
 
21 
shows the mean±s.e.m. (n=3 biological repeats, Mann-Whitney test, *=p<0.05) of the fold 
change in the ratio of firefly to renilla luciferase expression relative to the empty pcDNA 
transfection for each experiment. Note that unlike the 3’UTR of ZIKV, the 5’UTR does not 
contain consensus MSI1 binding sites.  
B) A representative western blot of HEK293T cells transfected with defined concentrations 
of an empty vector (pcDNA) and a MSI1 transgene (pcDNA-Msi1) as in Fig. S4A. Blots 
were probed with antibodies against MSI1. -tubulin serves as loading control.  
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Fig. S5.  MSI1 does not affect replication of H1N1 influenza virus. Viral RNA in 
HEK293T cells clones stably expressing a MSI1 transgene following infection with influenza 
virus (MOI:3 or MOI:10 FFU/cell, 48h). Refer to Figs. S11 and S12 for molecular 
characterization and ZIKV infection of the same HEK-MsiWT clones, respectively. n=2 
biological replicates at each MOI.  
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Fig. S6.  Characterisation of MSI1 KO U-251 cells.  
A) Wound closure assay of cells with indicated genotypes. Wound closure was measured by 
 
24 
time-lapse imaging in an automated fashion by the IncuCyte system. n=3 biological replicates 
are plotted as mean ± s.e.m. P-values: p=0.2 for parental vs. control, p<0.05 for control vs. 
KO1 and p<0.005 for control vs. KO2.  Values were obtained from Student’s t-test, unpaired, 
two-tailed.
B) Doubling times of cells with indicated genotypes were obtained by an IncuCyte live-cell 
imaging and analysis system. n=3 replicates are plotted as mean ± s.e.m. p values were 
obtained from Student’s t test, unpaired, two-tailed: *p<0.05, n.s= not significant. 
C) Representative plots of cell cycle profiles of KO1 and KO2 cells as determined by FACS.  
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Fig. S7. MSI1 expression is restricted to neural progenitors during human embryonic 
brain development.  
A) Immunohistochemistry of human embryonic brain at post conception week (pcw) 10. 
Tissue sections were stained with antibodies against MSI1 (red) and the neuron-specific -III 
tubulin (green). DNA is stained with DAPI (blue).  
B) Immunohistochemistry of human embryonic brain at pcw 10. Tissue sections were stained 
with antibodies against MSI1 (red) and the apical neural progenitor marker Nestin (green). 
DNA is stained with DAPI (blue). 
C) Tissue sections were stained with antibodies against MSI1 (red) and the neuron-specific -
III tubulin (green). DNA is stained with DAPI (blue). 
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Fig. S8. Clinical and molecular genetic data of MSI1A184V patients. 
A) Images of affected children (published with consent from the family). Box on right 
indicates occipito-frontal head circumference (OFHC). Normal range is white, range typical 
for MCPH is grey with blue lines indicating the affected children.  
B) Images show two representative T1-weighted MRI scans of patient 1 at age 4y. The brain 
architecture is normal. Note measurements of the cerebrum - reduction in brain volume is 
most evident for the cerebral cortices, and there are no congenital anomalies such as defects 
of neuronal migration. The left image is mid-sagittal and illustrates the normal structure and 
proportions of the brain regions and the right image is coronal at the level of the basal ganglia 
and shows normal cerebral cortex structure and proportions. Cerebral white and grey matter 
are normal for age.  
C) Pedigree of affected family. Consanguineous relationship is marked with double line.  
D) Location of point mutation in the MSI1 gene. Light and dark grey boxes correspond to 
UTRs and exons, respectively.   
E) Sanger sequencing traces of wild-type, parent (heterozygous) and affected patient 
(homozygous) samples.  
F) Alanine 184 in MSI1 is a highly conserved residue across species.  
G) Examples for premature chromosome condensation (PCC) in Giemsa-stained metaphase 
spreads prepared from patient 1’s primary lympocytes. Note condensed chromosomes in 
prophase-like cells. 14% of metaphases in patient cells and 6% in control cells were scored as 
PCC at the clinic. 
 
 
 
 
 
 
 
 
29   
 
30 
Fig. S9. MCPH1 downregulation is responsible for the PCC phenotype of MSI1-
deficient cells. 
A) Schematic representation of the long and short splice isoforms of MCPH1. 
B) MSI1 RNA immunoprecipitation (RIP) from U-251 cells with different genotypes. 
Western blot shows immunoprecipitations (IP) by rabbit IgG and MSI1 antibodies from U-
251 cells. Input represents 10% of whole cell extract. Western blot was probed with MSI1 
antibody. Graph below shows qPCR performed on bound RNA from IP. RIP values are 
presented as a percentage of input following subtraction of the IgG background. GAPDH 
serves as negative and NUMB as positive control. n=3 biological replicates. Bar chart depicts 
mean ± s.e.m.  
C) MCPH1 protein levels are reduced in MSI1-deficient cells. Western blot on top shows 
whole cell lysates from control, parent-of-patient- and patient-derived primary lymphocytes. 
Blots were probed with antibodies as indicated. Blot below shows whole cell extracts from 
cells treated with two different siRNAs targeting MSI1. Antibodies used for immunoblotting 
are indicated.  
D) Western blot shows whole cell extracts from cells treated with siRNAs targeting MSI1 or 
MCPH1. Antibodies used for immunblotting are indicated.  
E) Frequency of premature chromosome condensation (PCC) in U-251 cells with indicated 
genotypes. PCC refers to an increase in prophase-like cells, which can be distinguished by 
their condensed chromatin and intact nuclear envelope (by lamin-B staining) (as in Fig. S9F). 
p values were obtained from Fisher’s exact test.  
F) PCC in MSI1-depleted cells. Note intact nuclear envelope (as detected by Lamin-B 
antibody, green) and condensed chromatin (DNA is stained by Hoechst, blue).  
G) Western blot shows whole cell lysates of cells treated with siRNAs targeting MSI1 in 
combination with transgenes expressing MCPH1_S or MCPH1_L. Antibodies used for 
immunblotting are indicated. Western blot is representative of experiments shown in Fig. 
S9H.  
H) Graph depicts PCC frequency in MSI1-depleted cells expressing MCPH1_S or 
MCPH1_L transgenes. MCPH1_L and MCPH1_S were introduced 36h after addition of 
 
31 
MSI1 siRNAs and cells were fixed 36h later. Cells with indicated treatments and genotypes 
were scored by combining lamin-B antibody with DNA staining as in Fig. S9F. n=3 
biological replicates. p values were obtained from Student’s t test, unpaired, two-tailed: * 
p<0.05, ** p<0.005. 
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Fig. S10. MSI1 regulates translation of MCPH1.  
A) Relative levels of total MCPH1_L transcript in parent-of-patient (Msi1het) or patient-
derived lymphocytes (Msi1A184V) normalized to GAPDH. Bar chart depicts mean ± s.e.m. p 
values were obtained from Student’s t test, unpaired, two-tailed. The differences were not 
significant (n.s). 
B) Relative levels of total MCPH1_L transcript in WT and MSI1 KO U-251 cells normalized 
to GAPDH. Bar chart depicts mean ± s.e.m. p values were obtained from Student’s t test, 
unpaired, two-tailed. The differences were not significant (n.s). 
C) Absorbance (A254) profiles for continuous gradient fractionation of WT and MSI1 KO U-
251 cells.  
D) Distribution of sedimented GAPDH mRNAs throughout the gradients as quantified by 
qPCR. mRNA signal is normalized to cytosolic RNA content before fractionation. 
E) Distribution of sedimented MCPH1_L mRNAs throughout the gradients as quantified by 
qPCR. mRNA signal is normalized to cytosolic RNA content before fractionation.  
F) Western blot analysis of TCA-precipitated fractions (corresponding to Fig. S10C) probed 
with antibodies against MCPH1 and MSI1. Poly A-binding protein (PABP) was used to 
confirm the polysomal fractions. 
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Fig. S11. The A184V mutation impairs RNA binding by MSI1 and deregulates its 
targets in HEK293T cells.  
A) Western blots show MSI1 and MCPH1 levels in whole cell extracts of HEK293T cell 
lines. Multiple stable, single cell-derived clones of HEK293T expressing MsiWT or MsiAV 
transgenes were generated. WT and AV clones were matched according to expression levels 
based on the western blot (WT1, AV1: low; WT2, AV2: high). Western blots were probed 
with antibodies against MSI1 and MCPH1. p150 serves as loading control. Quantitation of 
MSI1 and MCPH1 signals are shown on graphs to the right. Note that due to its absence in 
parental and control cells, absolute values are shown for MSI1, whereas MCPH1 levels were 
normalized against levels in parental cells. 
B) qPCR from a MSI1 RNA immunoprecipitation (RIP) performed from the different 
HEK293T cell lines. RIP values are presented as a percentage of input following subtraction 
of the IgG background. GAPDH serves as negative and NUMB as positive control. Graph 
depicts mean±s.d. n=3 biological replicates. 
C) Doubling times of cells with indicated genotypes were obtained by an IncuCyte live-cell 
imaging and analysis system. n=3 replicates are plotted as mean ± s.e.m. p values were 
obtained from Student’s t test, unpaired, two-tailed. The differences were not significant for 
any of the genotypes. 
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Fig. S12. MSI1 expression increases susceptibility of HEK293T cells to ZIKV infection.  
A) Images show parental HEK293T cells, which lack endogenous MSI1, and HEK293T cells 
expressing a wild type MSI1 transgene (clones reported in Fig. S11) following PE243 ZIKV 
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infection. MOI:1 FFU/cell, 36h. Cells were stained with an antibody against flavivirus 
protein E. DNA is stained with Hoechst. Scale bar=50]m.  
B) Viral RNA levels in HEK293T cells following infection with PE243 (MOI: 1 FFU/cell, 
48h). n=3 biological replicates. P-values were obtained from Student t-test, unpaired, two-
tailed: * p<0.05, ** p<0.005, not significant (n.s.).  
C) Viral RNA load in HEK293T cells following infection with PE243 (MOI: 3 FFU/cell, 
48h). n=2 biological replicates.  
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Fig. S13. Proposed model to explain the role of MSI1 in MCPH and ZIKV-induced 
microcephaly. During normal fetal development (left panel) MSI1 maintains proliferation of 
neural precursors, a role that involves translational control of its cellular targets. It promotes 
expression of the MCPH proteins, CDK6 and MCPH1, and represses expression of NUMB 
and p21. In MSI1A184V patients (middle panel) mutant MSI1 does not bind its RNA targets 
effectively, thereby deregulating their expression. This impedes normal proliferation of 
neural precursors, produces fewer neurons, which causes microcephaly. Upon ZIKV 
infection (right panel), MSI1 binds the viral genome in neural precursors and stimulates its 
replication directly and/or indirectly, thus decimating this irreplaceable stem cell population, 
which leads to microcephaly. Moreover, in those rare cases when stem cells survive the 
infection, transient sequestration of MSI1 by ZIKV RNA may deregulate MSI1 targets and 
alter cell fate. In addition, the virus also causes a wide range of cytopathic effects in neural 
progenitors and surrounding cells, leading to inflammation and structural brain defects. 
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Table S1. TCNAG2.0 results listing the shared homozygous and concordant regions 
present in both affected children. All chromosome locations based on NCBI36/hg18 
human genome assembly. The homozygous segment containing the pathogenic mutation is 
shown in bold. 
 
Chromosome bands Size of region Start of region End of region 
1p21.3 – p13.1 19.5Mb 97,640,328 117,188,024 
2q31.3 – q34 30Mb 180,421,369 210,469,387 
2q37.2 - q37.3 6.6Mb 236,067,214 242,717,659 
3q13.11 - q25.2 48.6Mb 107,683,064 156,303,776 
4q22.1 - q24 18.4Mb 88,866,848 107,281,230 
5q11.2 - q12 10.4Mb 53,499,547 63,910,619 
5q13.3 - q22.2 36.7Mb 75,279,191 112,004,899 
8p11.23 – q12.3 24.7Mb 38,886,941 38,886,941 
12q15 - q21.1 4.6Mb 67,133,823 71,772,466 
12q23.2 - q24.31 23.3Mb 101,470,766 124,807,539 
13q31.1 – q32.2 16.2Mb 81,857,944 98,119,056 
17q23.2 – q24.2 10Mb 53,183,878 63,168,794 
18p11.32 – q1 19.5Mb 833,971 20,311,736 
18q21.33 – q22.3 11.8Mb 59,322,883 71,109,557 
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Table S2. The four homozygous mutations considered after autozygosity mapping and 
exome sequencing. All mutations were non-synonymous. Position as in GRCh37/hg19. The 
transcripts reported were NM_014420.2, NM_138287.3, NM_002442.2 and NM_001093.3. 
PolyPhen and SIFT were used to predict effects of amino acid substitutions. Brainspan data 
from http://www.brainspan.org indicates expression levels during human fetal brain 
development. 
Position Change Depth Gene  AA change PolyPhen SIFT Brainspan Mouse model 
8:42233261 G>A 20 DKK4  p.Arg67 Cys deleterious/0 probably damaging/1 very low no phenotype 
3:122287775 C>T 33 DTX3L  p.Thr280 Ile deleterious/0.01 possibly damaging/0.467 very low n/a 
12:120794806 G>A 26 MSI1  p.Ala184 Val deleterious/0 probably damaging/0.997 high 
defects in 
neuro- 
development 
12:109704152 C>G 23 ACACB  p.Ser2454 Arg deleterious/0.01 possibly damaging/0.269 very low n/a 
 
 
 
  
 
41 
Table S3. List of putative MSI1 binding sites in flavivirus 3’ UTRs. G/AU(1-3)AG 
consensus sites were mapped onto structural prediction of 3’UTRs from various flaviviruses 
from http://sergio14.github.io/Flaviviruses_RNA_Structures/Flavivirus-3UTR.svg#19 and 
(16). Only sites on accessible (i.e. not blocked by predicted pseudoknots) loop structures are 
listed. MBV:mosquito-borne viruses; TBV: tick-borne viruses; ISV: insect-specific viruses; 
NKV: no known vector viruses. 
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Table S4. Table of primers used to generate plasmids and perform qPCR in this study. 
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